A Phase 2 interventional study of IV Remodulin and Placebo in Persistent Pulmonary Hypertension of the Newborn, sponsored by United Therapeutics. Terminated at 14 sites in United States. Open to participants aged 1 Hour to 14 Days. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Persistent Fetal Circulation Syndrome · United States.
Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 2, and was the 14th registered.
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
Browse Persistent Fetal Circulation Syndrome studies →1 of the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States is open now. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages up to 12 mo · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Persistent Fetal Circulation Syndrome studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 1 Hour to 14 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.
Median enrollment 38 across the 12 interventional studies, 106 across the 4 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
United Therapeutics has 1 study filed under Persistent Fetal Circulation Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
This study was designed to investigate if the addition of Remodulin reduced the rate of clinical worsening (defined as the need for additional treatment targeting PPHN, need for extracorporeal mechanical oxygenation [ECMO], or death) in neonatal subjects with PPHN who did not show an adequate response to inhaled nitric oxide (iNO). This study was part of a pediatric investigation plan agreed upon by the EMA (EMEA 000207-PIP01-08-M08).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.
Drug: IV Remodulin
The starting dose was 1 ng/kg/min (not to exceed to 2 ng/kg/min) and was titrated by up to 2 ng/kg/min every 2 hours, as tolerated and clinically indicated by the Investigator. Doses were titrated and maximized throughout the study until the desired clinical effect was observed or to each individual subject's maximally tolerated dose. There was no maximum dose.
Drug: Placebo
Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
Also known as: Treprostinil
Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
Number of Subjects Experiencing Clinical Worsening
Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).
Time frame: From Baseline to Day 14
Change in Oxygenation Index (OI)
OI is an assessment of how much oxygen from the lungs enters the blood when a subject inhales, calculated as: mean airway pressure (MAP) multiplied by fraction of inspired oxygen (FiO2) divided by partial pressure of oxygen in the arterial blood (PaO2), then multiplying by 100. An OI of 15 or less indicates mild hypoxia, 16 to 25 indicates moderate hypoxia, 26 to 40 indicates severe hypoxia, and more than 40 indicates very severe hypoxia.
Time frame: From Baseline to Hours 12, 24, and 72; Days 7 and 14; and/or prior to study drug discontinuation/weaning
Change in P/F Ratio
PaO2/FiO2 ratio, also referred to as P/F Ratio, is a calculation used to assess the severity of hypoxemia, which is a condition characterized by low levels of oxygen in the blood. A low P/F ratio suggests that the patient's oxygen levels are compromised relative to the amount of oxygen being provided.
Time frame: From Baseline to Hours 12, 24, and 72
Change in Pre- and Post-ductal Oxygen Saturation (SpO2)
SpO2 is an assessment of how much oxygen is in the blood, measured by a pulse oximeter. Pre-ductal SpO2 is measured in the right hand or foot and is a reflection of the amount of oxygen flowing to the brain. Post-ductal SpO2 is measured in the left hand or foot, after the blood has mixed with less oxygenated blood from the rest of the body.
Time frame: From Baseline to Hours 6, 12, 24, and 72
Change in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
NT-proBNP is a hormone produced by the heart. Increased NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy individual.
Time frame: From Baseline to Days 1, 2, 3, 7, and 14 (or prior to hospital discharge)
Time to Clinical Worsening
Clinical worsening was assessed continuously during the study. Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).
Time frame: From Baseline to Day 56
Time to Initiation of ECMO
Start of ECMO was assessed continuously during the study. ECMO is a life-support therapy that oxygenates blood by passing it through an artificial lung. The start time of ECMO, if needed, was recorded for each subject.
Time frame: From Baseline to Day 56
Time to Discontinuation of Inhaled Nitric Oxide (iNO)
Discontinuation of iNO was assessed continuously during the study. iNO works by relaxing the blood vessels in the lungs, which makes it easier for oxygen to be delivered to the body. The stop time of iNO was recorded for each subject.
Time frame: From Baseline to Day 56
| Milestone | IV Remodulin | Placebo |
|---|---|---|
| Started | 21 | 21 |
| Completed | 15 | 18 |
| Not completed | 6 | 3 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Required ecmo prior to study drug administration | 1 | 0 |
Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).
| Participants | IV Remodulin | Placebo |
|---|---|---|
| Yes | 8 | 12 |
| No | 12 | 9 |
OI is an assessment of how much oxygen from the lungs enters the blood when a subject inhales, calculated as: mean airway pressure (MAP) multiplied by fraction of inspired oxygen (FiO2) divided by partial pressure of oxygen in the arterial blood (PaO2), then multiplying by 100. An OI of 15 or less indicates mild hypoxia, 16 to 25 indicates moderate hypoxia, 26 to 40 indicates severe hypoxia, and more than 40 indicates very severe hypoxia.
| units on a scale | IV Remodulin | Placebo |
|---|---|---|
| 12 Hours | -2.0 (-41 to 37) | -3.5 (-29 to 34) |
| 24 Hours | -8.5 (-40 to 23) | -5.5 (-30 to 58) |
| 72 Hours | -7.0 (-40 to 65) | -10.0 (-41 to 83) |
| Day 7 | -9.5 (-40 to 36) | -11.0 (-43 to 42) |
| Day 14 | -12.0 (-40 to 36) | -14.0 (-35 to 42) |
PaO2/FiO2 ratio, also referred to as P/F Ratio, is a calculation used to assess the severity of hypoxemia, which is a condition characterized by low levels of oxygen in the blood. A low P/F ratio suggests that the patient's oxygen levels are compromised relative to the amount of oxygen being provided.
| ratio | IV Remodulin | Placebo |
|---|---|---|
| 12 Hours | 0.11 (-0.5 to 10.5) | 0.10 (-2.3 to 4.1) |
| 24 Hours | 0.35 (-0.4 to 9.3) | 0.27 (-2.3 to 7.1) |
| 72 Hours | 0.50 (-0.4 to 4.8) | 0.65 (-2.3 to 7.5) |
SpO2 is an assessment of how much oxygen is in the blood, measured by a pulse oximeter. Pre-ductal SpO2 is measured in the right hand or foot and is a reflection of the amount of oxygen flowing to the brain. Post-ductal SpO2 is measured in the left hand or foot, after the blood has mixed with less oxygenated blood from the rest of the body.
| percentage of oxygen | IV Remodulin | Placebo |
|---|---|---|
| 6 Hours | 3.0 (-6 to 13) | 1.0 (-10 to 7) |
| 12 Hours | 3.0 (-7 to 17) | 0.5 (-7 to 12) |
| 24 Hours | 3.0 (-12 to 15) | 1.0 (-17 to 11) |
| 72 Hours | 0.0 (-4 to 16) | 1.5 (-21 to 8) |
NT-proBNP is a hormone produced by the heart. Increased NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy individual.
| pg/mL | IV Remodulin | Placebo |
|---|---|---|
| Day 1 | -1577.00 (-21322.0 to 43388.0) | -1378.00 (-23206.0 to 17923.0) |
| Day 2 | -1955.00 (-24637.0 to 34599.0) | -4090.00 (-37390.0 to 14163.0) |
| Day 3 | -252.00 (-24623.0 to 30629.0) | -4090.00 (-49200.0 to 13550.0) |
| Day 7 | 484.00 (-24623.0 to 19970.0) | -11312.00 (-65387.0 to 12299.0) |
| Day 14 | -719.00 (-26283.0 to 56529.0) | -9003.00 (-65387.0 to 12299.0) |
Clinical worsening was assessed continuously during the study. Clinical worsening was a composite endpoint defined by the occurrence of 1 of the following: death, initiation of ECMO per institutional policies, or need for additional treatment (initiation of additional targeted pulmonary vasodilator therapy).
| days | IV Remodulin | Placebo |
|---|---|---|
| Time to Clinical Worsening | 3.0 (1 to 8) | 3.0 (1 to 13) |
Start of ECMO was assessed continuously during the study. ECMO is a life-support therapy that oxygenates blood by passing it through an artificial lung. The start time of ECMO, if needed, was recorded for each subject.
| days | IV Remodulin | Placebo |
|---|---|---|
| Time to Initiation of ECMO | 2.5 (1 to 8) | 3.0 (1 to 5) |
Discontinuation of iNO was assessed continuously during the study. iNO works by relaxing the blood vessels in the lungs, which makes it easier for oxygen to be delivered to the body. The stop time of iNO was recorded for each subject.
| days | IV Remodulin | Placebo |
|---|---|---|
| Time to Discontinuation of Inhaled Nitric Oxide (iNO) | 7.5 (1 to 12) | 7.0 (1 to 11) |
Collected over Adverse events (AEs) were captured from when the subject signed the informed consent form until the subject completed the study or was withdrawn from the study, up to 56 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Remodulin | 4/20 (20%) | 8/20 (40%) | 19/20 (95%) |
| Placebo | 2/21 (9.5%) | 3/21 (14.3%) | 17/21 (81%) |
| Event | IV Remodulin | Placebo |
|---|---|---|
| Cardio-respiratory arrestCardiac disorders | 1/20 | 0/21 |
| Congenital diaphragmatic herniaCongenital, familial and genetic disorders | 1/20 | 0/21 |
| HypotensionVascular disorders | 1/20 | 0/21 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/20 | 1/21 |
| Laryngeal stenosisRespiratory, thoracic and mediastinal disorders | 1/20 | 0/21 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/20 | 0/21 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 1/20 | 1/21 |
| Pyloric stenosisCongenital, familial and genetic disorders | 1/20 | 0/21 |
| Renal impairmentRenal and urinary disorders | 1/20 | 0/21 |
| SepsisInfections and infestations | 1/20 | 0/21 |
| Event | IV Remodulin | Placebo |
|---|---|---|
| HypotensionVascular disorders | 6/20 | 3/21 |
| AnaemiaBlood and lymphatic system disorders | 5/20 | 4/21 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/20 | 1/21 |
| Drug withdrawal syndrome neonatalGeneral disorders | 3/20 | 0/21 |
| Alanine aminotransferase increasedInvestigations | 3/20 | 0/21 |
| Aspartate aminotransferase increasedInvestigations | 3/20 | 0/21 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 3/20 | 1/21 |
| ConstipationGastrointestinal disorders | 2/20 | 0/21 |
| SeizureNervous system disorders | 2/20 | 1/21 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/20 | 1/21 |
Intent-to-Treat Population
| Age, Continuous(days) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Median | 2.0 (1 to 6) | 3.0 (1 to 6) | 3.0 (1 to 6) |
| Sex: Female, Male(Participants) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Female | 10 | 10 | 20 |
| Male | 10 | 11 | 21 |
| Ethnicity (NIH/OMB)(Participants) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 17 | 19 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 10 | 15 |
| White | 12 | 11 | 23 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Gestational Age(weeks) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Median | 39.00 (34.0 to 41.0) | 39.00 (34.0 to 41.2) | 39.00 (34.0 to 41.2) |
| Birth Weight(kg) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Median | 3.08 (2.2 to 4.8) | 3.06 (2.2 to 4.5) | 3.06 (2.2 to 4.8) |
| Oxygenation Index(units on a scale) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Median | 25.5 (4 to 46) | 22.0 (6 to 46) | 23.0 (4 to 46) |
| Fraction of Inspired Oxygen (FiO2)(percentage of oxygen) | IV Remodulin | Placebo | Total |
|---|---|---|---|
| Median | 100.0 (75 to 100) | 100.0 (35 to 100) | 100.0 (35 to 100) |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Sep 2022, 85 months.
Results were first posted in Mar 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Persistent Fetal Circulation Syndrome →